Yüklüyor......
Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2018-02-01
|
| Seri Bilgileri: | Therapeutic Advances in Vaccines and Immunotherapy |
| Online Erişim: | https://doi.org/10.1177/2515135518763280 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|